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Abstract
Background: Following genital chlamydial infection, an early T helper type 1 (Th1)-associated
immune response precedes the activation and recruitment of specific Th1 cells bearing distinct
chemokine receptors, subsequently leading to the clearance of Chlamydia. We have shown that
CCR5, a receptor for CCL5, is crucial for protective chlamydial immunity. Our laboratory and
others have also demonstrated that CCL5 deficiencies found in man and animals can increase the
susceptibility and progression of infectious diseases by modulating mucosal immunity. These
findings suggest the CCR5-CCL5 axis is necessary for optimal chlamydial immunity. We
hypothesized CCL5 is required for protective humoral and cellular immunity against Chlamydia.
Results: The present study revealed that CCR5 and CCL5 mRNAs are elevated in the spleen, iliac
lymph nodes (ILNs), and genital mucosa following Chlamydia muriduram challenge. Antibody (Ab)-
mediated inhibition of CCL5 during genital chlamydial infection suppressed humoral and Th1 > Th2
cellular responses by splenic-, ILN-, and genital mucosa-derived lymphocytes. Antigen (Ag)-specific
proliferative responses of CD4+ T cells from spleen, ILNs, and genital organs also declined after
CCL5 inhibition.
Conclusion:  The suppression of these responses correlated with delayed clearance of C.
muriduram, which indicate chlamydial immunity is mediated by Th1 immune responses driven in
part by CCL5. Taken together with other studies, the data show that CCL5 mediates the temporal
recruitment and activation of leukocytes to mitigate chlamydial infection through enhancing
adaptive mucosal humoral and cellular immunity.
Background
Chlamydia trachomatis is the most common sexually trans-
mitted bacterial pathogen in the United States; infection
results in devastating sequelae, including pelvic inflam-
matory disease and infertility. Animal models and clinical
studies of infected patients have indicated that protective
chlamydial immunity is primarily mediated by Th1
responses [1-3]. The induction of such immunity involves
rapid recruitment and activation of certain effector
immune cells, specifically Th1 cells and dendritic cells
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(DCs) into the local genital mucosa to clear the infection,
arrest ascending disease, and prevent major complications
[1,4-7]. In addition, certain complimentary B cell func-
tions – principally Ab-mediated enhancement of Ag pres-
entation – lead to activation of Ag-specific Th1 cells
dependent in part by Fc-receptor-mediated events [1,8].
Thus, both cell-mediated and humoral immune responses
are required for long-term protection against Chlamydia.
With the major elements of protective anti-Chlamydia
immunity defined, a number of candidate vaccines have
been described [1]. Chemokines have emerged as impor-
tant factors and possible mucosal adjuvants that function
in lymphocyte activation and recruitment [9-11]. Indeed,
a qualitative relationship exists between the class of chem-
okines secreted following infection, the type of immune
response (cellular or humoral immunity) elicited, and the
fate of the host following infection [12-15]. The profile of
chemokine expression serves as a reliable indicator of
immune response type (i.e., Th1 vs. Th2). In this respect,
the CCL5-CCR5 axis has been demonstrated to be prefer-
entially involved in the activation and function of Thl
cells [10,16,17].
CCL5 is secreted by epithelial cells, macrophages, fibrob-
lasts, platelets, and activated T cells [18]. This CC chemok-
ine is known to regulate T cell differentiation and polarize
Th1 >> Th2 subtypes [10,13,18,19] as well as numerous
physiological functions of leukocytes including migra-
tion. Polymorphisms in CCR5 and CCL5 modulate
immune responses as well as susceptibility and progres-
sion to HIV-1 and AIDS, respectively [20,21]. We also
showed that many of the deleterious complications of
genital chlamydial infection, due to Th1-mediated
inflammation, are not present in individuals with the
ccr5Δ32 mutation or in CCR5-deficient mice [22]. CCR5
expression following genital chlamydial infection is fol-
lowed by an early Th1-like response that precedes activa-
tion and mucosal recruitment of Ag-specific Th1 cells
necessary for clearance of Chlamydia [23]. These findings
indicate that CCL5 might be important for inducing pro-
tective immunity against Chlamydia. However, it is not
certain what affect CCL5 deficiency would have on
chlamydial disease. We tested the hypothesis that CCL5 is
essential for inducing adaptive mucosal immunity against
Chlamydia by Ab inhibition using a reliable mouse model
of genital chlamydial infection. Results revealed CCL5
supports the induction of Th1 cytokine and immunoglob-
ulin IgG2a as well as IgA responses against Chlamydia.
Results
Expression of chemokines after genital Chlamydia 
infection
CCL5, CCR5, and IFN-γ mRNAs were measured by quan-
titative RT-PCR analysis after genital chlamydial infection.
A significant increase in CCR5, CCL5, and IFNγ gene
expression in the spleen and ILN was observed 7 days after
genital infection when compared with levels before infec-
tion (Figure 1). These mRNA levels modestly declined at
inductive sites 14 days after infection. CCR5, but not
CCL5 or IFN-γ mRNA expression by fallopian tube-,
uterus-, and cervix- derived lymphocytes were considera-
bly higher than levels before infection. Indeed, CCR5
mRNA expression by fallopian tube lymphocytes was sig-
nificantly higher 7 and 14 days post infection. These data
suggest that increases in CCL5, CCR5, and IFN-γ mRNA
expression during early stages of infection at inductive
sites (i.e., spleen and ILN) preceded CCR5 expression at
effectors sites (i.e., fallopian tube(s), uterus, and cervix).
The pattern of CCL5 and CCR5 as well as IFN-γ illustrates
how this chemokine axis coincides with both the innate
(recognition phase, 0 to 7 days) and adaptive (activation,
effector, and decline/homeostasis phases) immune
responses to this pathogen and associated inflammation.
Proliferative responses of C. muridarum genital infection 
modulated by CCL5 inhibition
We next characterized C. muridarum-specific proliferative
responses of T helper cells isolated from the spleen, ILNs,
fallopian tube(s), uterus, and cervix, 42 days after chal-
CCL5, CCR5, and IFN-γ mRNA expression during Chlamydia  infections Figure 1
CCL5, CCR5, and IFN-γ mRNA expression during 
Chlamydia infections. Groups of female BALB/c mice chal-
lenged with C. muridarum and total RNA was isolated from 
lymphocytes isolated from the spleen, ILNs, fallopian tubes, 
uterus, and cervix of each mouse, under sterile conditions 
before or 7 and 14, 21 and 42 days after challenge. The levels 
of CCL5, CCR5 and IFN-γ mRNA expression were ascer-
tained after RT-PCR analysis. Log10 copies of transcripts 
were expressed relative to the actual copies of 18S rRNA ± 
SEM. Experiments were repeated 3 times to yield 15 mice 
per group. Asterisks (*) indicate significant differences (p < 
0.01) between tissues from naïve mice.BMC Microbiology 2008, 8:136 http://www.biomedcentral.com/1471-2180/8/136
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lenge. CD4+ T cells isolated from these mucosal and sys-
temic immune compartments of C. muridarum-infected
and control Ab-treated mice exhibited marked increases in
Ag-specific proliferative responses compared to disease-
free (uninfected) or C. muridarum-infected and anti-CCL5
Ab-treated mice (Figure 2). Notably, systemic and
mucosal inductive sites of the spleen and ILN, respec-
tively, contained Ag-specific CD4+ T cells that significantly
proliferated after C. muridarum re-stimulation. These
results suggest that CCL5 is required for optimal genera-
tion of Chlamydia-specific CD4+ T cells that proliferate
after Ag recognition.
CCL5 modulation of Chlamydia-specific humoral 
responses
To test the role of CCL5 in Th1-biased humoral responses
to genital infection, we measured Chlamydia-specific IgG1,
IgG2a, IgG2b, IgG3 and IgM Abs in sera as well as Ag-spe-
cific IgA and IgG Abs in vaginal washes. Infected mice that
received control Ab displayed significantly higher levels of
Chlamydia-specific serum IgG2a, followed by IgG2b
responses than compared to similar mice that received
anti-CCL5 Ab or mock-infected (i.e., naïve) mice (Figure
3). Analysis of vaginal secretions revealed a significant
increase in Ag-specific IgA Ab responses in C. muridarum-
challenged mice that received control Ab when compared
with similar mice that received anti-CCL5 Ab or unin-
fected animals. These results indicate C. muridarum infec-
tion enhanced Th1-biased humoral responses and CCL5
blockade attenuated Chlamydia-specific IgG2a serum
responses as well as vaginal IgA responses.
T helper cytokine responses and C. muridarum shedding
Genital Chlamydia infection up-regulated Ab responses as
well as splenic and ILN CD4+  T cell proliferative
responses. We next examined whether these effects were
mediated in part through T helper cytokine responses. IL-
2 secreted by Ag-stimulated splenic CD4+ T cells from
infected mice that received control Ab was significantly
higher than levels from cells isolated from similar mice
that received anti-CCL5 Ab or uninfected mice (Figure 4).
The secretion of IFN-γ from splenic, but not ILN, CD4+ T
cells from C. muridarum-infected and control Ab-treated
were considerably higher than T helper cells isolated from
similar mice treated with anti-CCL5 Ab or uninfected ani-
mals. Chlamydial infection of mice lead to the develop-
ment of CD4+ T cells that significantly secreted IL-6, IL-10,
and GM-CSF, but not IL-4, in response to C. muridarum re-
stimulation. Anti-CCL5 Ab-treated mice infected with C.
Chlamydia-specific CD4+ T cell proliferation Figure 2
Chlamydia-specific CD4+ T cell proliferation. Groups 
of naïve or female BALB/c mice challenged with C. muridarum 
and received 100 μl of control Ab or anti-CCL5 Ab solution 
every 3 days. Following sacrifice 42 days after challenge, 
spleen-, ILN-, fallopian tubes-, uterus-, and cervix-derived 
CD4+ T cells were purified and cultured at a density of 5 × 
106 cells/ml with 106 cells/ml of γ-irradiated feeder spleno-
cytes for 3 days. Proliferation of CD4+ T cells was measured 
by BrdU incorporation. The data presented are the mean 
OD450 for proliferative ± SEM of quadruplicate cultures. 
Experiments were repeated 3 times to yield 15 mice per 
group. Asterisks (*) indicate statistically significant differences 
(p < 0.01) between untreated, control Ab-treated mice and 
mice treated with anti-CCL5 Ab.
Serum and vaginal Ab responses of mice infected with genital  Chlamydia Figure 3
Serum and vaginal Ab responses of mice infected 
with genital Chlamydia. Groups of naïve or female BALB/c 
mice challenged with C. muridarum and received 100 μl of 
control Ab or anti-CCL5 Ab solution every 3 days. Following 
sacrifice 42 days after challenge, Chlamydia-specific serum and 
vaginal Ab responses of mice were determined by ELISA that 
was capable of detecting > 20 pg/ml of IgM, IgG, IgA, and IgG 
subclass Abs. The data presented are the mean concentra-
tion of IgG1, IgG2a, IgG2b, IgG3, IgM, IgG, or IgA ± SEM of 
three separate experiments. Experiments were repeated 3 
times to yield 15 mice per group. Asterisks (*) indicate statis-
tically significant differences (p < 0.01) between untreated 
and control Ab- or anti-CCL5 Ab-treated mice.BMC Microbiology 2008, 8:136 http://www.biomedcentral.com/1471-2180/8/136
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muridarum resulted in T helper cells with reduced IL-6, IL-
10, and GM-CSF secretion following Ag re-stimulation
when compared to CD4+ T cells from similar mice treated
with control Ab; however, the secretion pattern of Th2
cytokine responses by CD4+ T cells isolated from ILNs did
not significantly change. These results indicate that C.
muridarum  infection invoked splenic, but not ILNs,
Chlamydia-specific CD4+  T cells that secreted Th1
cytokines as well as IL-6, IL-10, and GM-CSF, which were
reduced by CCL5 blockade. The extent of chlamydial
infection, determined by C. muridarum detected in cer-
vico-vaginal swabs, was significantly higher in mice
receiving anti-CCL5 Ab treatment than compared to con-
trol mice (Figure 5). However, all mice resolved chlamy-
dial infection in < 90 days.
Discussion
Th1-mediated immune responses are essential to control
the chlamydial infection [22]. It has been shown in previ-
ous studies that CCL3, CCL4 and CCL5 enhance adaptive
immunity through Th1 cytokine and co-stimulatory mol-
ecule modulation [10,11,15,16]. In this study, we demon-
strate some of the cellular and molecular mechanisms of
CCL5-mediated chlamydial immunity. Importantly, IFN-
γ mRNA was not significantly elevated 14 days after C.
muridarum  infection. IL-12p40 mRNA expression coin-
cided with CCL5, but typically preceded IFN-γ mRNA
expression (data not shown). Indeed, early genital clear-
ance of Chlamydia has been shown to occur in an IL-12-
dependent and IFN-γ-independent fashion [24]; so, fur-
ther studies will be required to dissect the roles of IL-12
and CCL5 in Chlamydia  clearance and immunity. The
present study shows that 7 days after genital Chlamydia
infection, CCL5, CCR5, and IFNγ mRNA levels were ele-
vated in inductive sites, while CCR5 mRNA expression
was higher in the fallopian tubes than in the uterus and
cervix. To this end, similar yet differential chemokine
expression patterns have been reported within anatomi-
cally distinct regions [25].
CD4+ Th1 cells (and associated cytokines, chemokines,
etc.) are critical elements in the immune response, stimu-
T helper cytokine secretion by CD4+ T cells from Chlamydia- infected mice Figure 4
T helper cytokine secretion by CD4+ T cells from 
Chlamydia-infected mice. Groups of naïve or female 
BALB/c mice challenged with C. muridarum and received 100 
μl of control Ab or anti-CCL5 Ab solution every 3 days. Fol-
lowing sacrifice 42 days after challenge, spleen- and ILN-
derived CD4+ T cells from these mice were purified and cul-
tured at a density of 5 × 106 cells/ml with 106 cells/ml of γ-
irradiated feeder splenocytes for 3 days. Cytokines present 
in cultured supernatants were determined by ELISA that was 
capable of detecting < 10 pg of IL-2, IFN-γ, IL-4, IL-6, IL-10, 
or GM-CSF. The data presented are the mean cytokine (pg/
ml) ± SEM of quadruplicate cultures. Asterisks (*) indicate 
statistically significant differences (p < 0.01) between 
untreated and control Ab- or anti-CCL5 Ab-treated mice.
Changes in Chlamydia-shedding Figure 5
Changes in Chlamydia-shedding. Mice treated with con-
trol Ab or anti-CCL5 Ab were infected with C. muridarum. 
The status of infection was monitored for live organism 
shedding by culturing periodic cervico-vaginal swabs from 
individual mice every week for 42 days after challenge. 
Chlamydia present in swabs were detected by infecting 
McCoy cells with vaginal swab rinses and staining infected 
monolayer with FITC-labeled, genus-specific, anti-Chlamydia 
Abs to count inclusion bodies (> 10 IFUs/ml) by direct 
immuno-fluorescence. BD indicates the presence of Chlamy-
diae was below this level of detection. Experiments were 
repeated 3 times to yield 15 mice per group. Asterisks (*) 
indicate statistically significant differences (p < 0.01) between 
untreated and control Ab- or anti-CCL5 Ab-treated mice.BMC Microbiology 2008, 8:136 http://www.biomedcentral.com/1471-2180/8/136
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lated by an ascending C. trachomatis infection in the
female genital tract [26]. Indeed, studies of chlamydial
infection in knockout mice support the importance of
class II MHC, CD4, IL-12, IFN-γ, and IFN-γ receptor for
chlamydial immunity [27-30]. Our data suggest that
CCL5 interactions are comparably important and mediate
the temporal recruitment and activation of T cells to miti-
gate chlamydial infection through protective mucosal
adaptive immunity by enhancing Th1 >> Th2 humoral
and cellular immune responses.
CCL3 and CCL4 are also CCR5 ligands, but these chemok-
ines were not remarkably elevated compared to CCL5,
which was the most abundant CCR5 ligand expressed dur-
ing the early stages (i.e., < 7 days) of chlamydial infection.
CCL5 is an important factor in the homing of lym-
phocytes that express CCR5, CCR4, CCR3 and CCR1 [31-
33]. It was also demonstrated from our earlier studies that
CCL5 can increase the proliferation and activation of Ag
stimulated T lymphocytes [10]. These findings coincide
with marked increases in CCL5 and IFN-γ production by
CD4+ T cells during chlamydial infection. It is also plausi-
ble that CCL5 blockade might reduce the ability of innate
immune cells (e.g., NK cells, macrophages, etc.) to
respond to C. muriduram challenge. Previously, we dem-
onstrated that CCL5 inhibition decreased the numbers of
NK1.1+ and CD11b+ leukocytes at mucosal effector sites
following pneumococcal challenge [34]. However, T cells
were the primary lymphocyte-subtype that were reduced
following CCL5 blockade during the hyper cellular
response to Streptococcus pneumoniae in mice.
Genital Chlamydia infection of mice enhanced Ag-specific
Abs in serum and vaginal secretions as well as proliferative
cytokine responses by CD4+ T cells isolated from systemic
and mucosal compartments. High levels of IgA in cervical
secretions in infected women correlate with low numbers
of C. trachomatis shedding and B cells are required to elim-
inate Chlamydia in a secondary infection [35]. We have
previously shown that CCL5 induces Ag-specific titers of
IgG2a, followed by IgG2b, IgG3, and IgG1 [10], CCL3 and
CCL4 enhance Ag-specific IgG1 and IgG2b responses [11].
In this study, Chlamydia  infection enhanced IgG2a Ab
responses, which were reduced after CCL5 inhibition.
This highlights the importance of this chemokine in Th1-
associated Ab responses against Chlamydia.
The precise cytokine signals required for S-IgA production
are not completely understood and studies show both
Th1-and Th2-type cell-derived cytokines are important for
S-IgA production [36-38]. We have previously shown that
chemokines like XCL1 and CCL5 induce IgA production
[9,10]. The sharp IgA Ab response generated by Chlamy-
dia-infected mice also correlated with the predominant
Th1 >> Th2 cytokine response induced by this infection,
which were reduced by CCL5 blockade. These results sug-
gest that CCL5 is required in part for optimal Chlamydia-
specific IgA Ab responses during C. muridarum infection.
Mucosal, but not serum, IgA Abs were selectively elevated
after  C. muridarum challenge, presumbably due to the
compartmentalized common mucosal immunity system.
In particular, IgA Ab-secreting cells predominantly popu-
late the lamina propria of the mucosa. In contrast,
Chlamydia-specific IgG Abs were not detected in vaginal
secretions. This confirms other studies that show vaginal
Chlamydia-specific IgG Abs are not present at high levels
(relative to IgA) in vaginal washes after C. muridarum chal-
lenge [39,40]. However, intranasal, subcutaneous or tran-
scutaneous immunization using mucosal adjuvants can
induce vaginal wash Ag-specific IgG Ab titers that are com-
parable to those of IgA [9,41-45].
IFN-γ production is often associated with IgG2a produc-
tion [46] and may account for the systemic humoral
responses against Chlamydia following vaginal challenge.
In the present study, Chlamydia infection induced a pro-
found IgG2a Ab response compared to other IgG subclass
Abs. The analysis of mucosal and systemic responses
revealed a bias toward Th1 >> Th2 type of responses.
While little is known regarding Ag-specific CD4+ T cell (IL-
4 and GM-CSF) secretory responses during Chlamydia
infection, we show that these T helper cytokines were
increased during chlamydial infection. CCL5 blockade
diminished these cellular responses along with C. muri-
darum-specific CD4+ T cell secretion of IFN-γ and IL-2.
Contradictory studies demonstrated the ability of CCL5 to
promote both Th1-and Th2-type responses. It was
reported that anti-CCL5 Ab treatment in mice decreased
mycobacterial-inducible Th2-type lesions while increas-
ing schistosomal-inducible Th2-type granulomas [47].
However, studies from our laboratory suggest CCL5
enhances mucosal and systemic humoral responses
through help provided by Th1-type cytokines and select
Th2-type cytokines, with CCL5 promoting Th1 and Th2
responses [10]. The results in the present study suggest
that CCL5 is required for optimal Th1 cellular responses
against and clearance of Chlamydia. These results corrobo-
rate our previous findings that CCR5-dependent mucosal
immune responses are required for the efficient clearance
of genital chlamydial infection, while functional CCR5
expression reduces infertility as a pathologic consequence
of Th1-mediated inflammation associated with infection
[22].
The ccl5 gene has a number of physiologically relevant
single nucleotide polymorphisms that affect its function
and expression. In particular, the In1.1T/C haplotype of
ccl5 is highly prevalent (~37%) in African Americans, thanBMC Microbiology 2008, 8:136 http://www.biomedcentral.com/1471-2180/8/136
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compared to Americans of European origin (~0.3%), and
results in significantly lower CCL5 expression [48]. This
has been attributed to some of the health disparities
between these ethic/racial groups; specifically, higher
human immunodeficiency virus (HIV) susceptibility and
faster progression to acquired immune deficiency syn-
drome (AIDS). Similar to the ccr5Δ32 polymorphism, the
data in this study and others suggest diminished CCL5-
CCR5 interactions could yield reduced fallopian tube
scarring, but could also result in higher transmission/
shedding of Chlamydia  via decreased chlamydial clear-
ance. It is plausible that a host with a modestly compro-
mised innate immune system would on one hand – avoid
infertility by mounting reduced Th1 responses and on the
other – be unable to optimally clear a chlamydial infec-
tion. This would provide an evolutionary rationale for not
only ccr5Δ32 and In1.1T/C ccl5 polymorphisms, but also
the propagation and transmission of Chlamydia. No
doubt, demonstration of this postulate will require addi-
tional and extensive studies.
Conclusion
Understanding the cellular and molecular mechanisms
that CCL5 uses to modulate mucosal immunity is essen-
tial to better understanding the pathogenesis of chlamy-
dial infection. We tested the hypothesis that CCL5 is
essential for inducing adaptive mucosal immunity against
Chlamydia. We conclude that CCL5 supports the induc-
tion of Th1 cytokine and IgG2a Ab as well as IgA Ab
responses against Chlamydia. The suppression of CCL5
correlated with delayed clearance of C. muriduram infec-
tion, which suggests chlamydial immunity is mediated by
Th1 immune responses driven in part by CCL5.
Methods
Chlamydia stocks
Stocks of the Chlamydia muridarum (trachomatis agent for
mice) were prepared by propagating elementary bodies
(EBs) in McCoy cells and used to infect mice as previously
described [49]. The stocks were tittered by infecting
McCoy cells with varying dilutions of EBs. The infectious
titer was expressed as inclusion-forming units per millili-
ter (IFU/ml).
Anti-CCL5 antibody production
Murine anti-CCL5 was produced as previously described
[34]. Briefly, rabbits were immunized with murine CCL5
(Pepro-Tech) and the hyper immune CCL5 antisera
obtained was yielded titers of ~1:106 such that 10 μl of
rabbit CCL5 antiserum neutralized 20 ng of CCL5. This
antiserum was titrated by direct ELISA, and no cross-reac-
tivity was detected when tested against other CCR5 lig-
ands, chemokines and cytokines. Subsequently, antisera
were heat-inactivated and purified using an IgG isotype-
specific protein A column (Pierce). Anti-CCL5 Ab titers
were adjusted to 1 : 4 × 105 (i.e., 50× dilution) in PBS (Ab
solution) for CCL5 blocking experiments. Similarly pre-
pared normal or preimmune rabbit serum was used to
generate the control Ab solution.
Animal infection, Ab treatment, and analysis of disease 
course
Female BALB/c mice, ages 6 to 8 weeks, were purchased
from Jackson Laboratory and used to establish a colony at
the Morehouse School of Medicine animal facility. The
animals were housed and maintained in isolator cages
under specific-pathogen-free housing conditions. The
guidelines proposed by the Committee for the Care of
Laboratory Animal Resources Commission of Life Sci-
ences-National Research Council were followed to mini-
mize animal pain and distress. These studies were
approved by the Morehouse School of Medicine Institu-
tional Animal Care and Use Committee (IACUC). Seven
days prior to infection, mice received 2.5 mg of medroxy-
progesterone acetate (Depo-Provera; The Upjohn Co.) by
subcutaneous route in 100 μl of PBS [50]. Groups were
intravaginally infected with 5 × 104 IFU of C. muridarum
under phenobarbital anesthesia, whereas uninfected con-
trol mice received only phosphate buffered saline (PBS).
Mice (15 mice per group) received 100 μl of either control
or anti-CCL5 Abs by intraperitoneal injection, 24 hrs
before chlamydial infection and every 72 hrs thereafter.
The extent of unresolved chlamydial infection was moni-
tored by taking cervico-vaginal swabs from individual
mice every week until 42 days after the challenge [22].
Briefly,Chlamydia  present in swabs were detected by
infecting McCoy cells vaginal/swab rinses and staining
infected monolayer with fluorescein isothiocyanate
(FITC)-labeled, genus-specific, anti-Chlamydia Abs (Kall-
estad Diagnostics) to verify inclusion bodies (> 10 IFUs/
ml) by direct immuno-fluorescence [49].
Sample, tissue, and cell collection
Vaginal cavities were rinsed three times with 50 μl of PBS
to obtain mucosal secretions. Blood collected by retro-
orbital bleeding and serum was separated following cen-
trifugation. Serum and mucosal secretions were collected
on 0, 7, 14, and 42 days post challenge and analyzed by
ELISA. Following sacrifice by CO2 inhalation, spleen, ILN,
fallopian tube(s), uterus, and cervix tissues were asepti-
cally removed and single-cell suspensions were prepared
by passing tissues through a sterile wire screen to quantify
mRNA expression and T helper responses. Reproductive
tract tissues were further disrupted to generate single cell
suspensions by stirring in collagenase type IV (Sigma) in
RPMI 1640 (collagenase solution) at 37°C for 30 min.
Lymphocytes were further purified using a discontinuous
Percoll (Pharmacia) gradient, collected at the 40/75%
interface. CD4+ T cells were enriched using Mouse CD4
Cellect® plus columns according to manufacturer's proto-BMC Microbiology 2008, 8:136 http://www.biomedcentral.com/1471-2180/8/136
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col (Biotex Laboratories). Cell suspensions were washed
twice in RPMI 1640 and lymphocytes were maintained in
medium supplemented with 10 ml/L of nonessential
amino acids (Mediatech), 1 mM sodium pyruvate
(Sigma), 10 mM HEPES (Mediatech), 100 U/ml penicil-
lin, 100 μg/ml streptomycin, 40 μg/ml gentamycin
(Elkins-Sinn), 50 μM mercaptoethanol (Sigma), and 10%
fetal calf serum (FCS) (Atlanta Biologicals).
Chlamydia-specific T helper cell responses
Purified CD4+ T cells were cultured at a density of 5 × 106
cells/ml with 106 cells/ml γ-irradiated (3,000 rads) naïve
splenic feeder cells in complete medium in the presence
or absence of 10 μg/ml of UV-inactivated C. muridarum
inclusion bodies (IBs) as Ag at 37°C in 5% CO2. After 3
days of culture, cells were pulsed with BrdU labeling solu-
tion and incorporation was detected by ELISA (Roche
Molecular Biochemical). Similarly, cell culture superna-
tants were collected 3 days after culture and assayed for
cytokine secretion by Luminex assay [34].
Anti-Chlamydia Ab detection in serum and vaginal washes
Chlamydia-specific serum IgG subclass antibodies and vag-
inal wash IgA levels were quantified 6 weeks after chal-
lenge by ELISA [10]. Briefly, 96-well Falcon ELISA plates
(Fisher Scientific) were coated with 100 μl of anti-IgG or
IgA Ab (BD-PharMingen) or 10 μg/ml of UV-inactivated
C. muridarum IBs in PBS O/N at 4°C and blocked with
10% FCS in PBS for 2 hrs at RT. IgM, IgG subclasses or IgA
standards, and experimental samples were serially added
after diluted with PBS. After O/N incubation at 4°C and
three washes using PBS containing 0.05% Tween 20 (PBS-
T), Ag-specific titers of IgM, IgG, IgA, or IgG subclass Abs
were determined following the addition of biotinylated
detection Abs (BD-PharMingen). After incubation and
wash steps, anti-biotin HRP Ab (Vector Laboratories Inc.,
Burlingame, CA) in PBS-T was added to detection wells
and incubated for 1 hr at RT. Following incubation, all
plates were washed 6 times and the color reaction was
developed by adding 100 μl of 1.1 mM 2,2'-azino-bis(3)-
ethylbenzthiazoline-6-sulfonic acid (Sigma) in 0.1 M cit-
rate-phosphate buffer (pH 4.2) containing 0.01% H2O2
(ABTS solution).
Cytokine detection
The presence of the following T helper cell-derived
cytokines in culture supernatants was determined by
Beadlyte™ mouse multi-cytokine detection system kit
(BioRad): interleukin (IL)-2, IL-4, IL-6, IL-10, granulocyte
monocyte cell stimulating factor (GM-CSF), and inter-
feron (IFN)-γ. Filter-bottom ELISA plates (BioRad) were
rinsed with 100 μl of Bioplex assay buffer and the buffer
was removed using a Millipore™ multiscreen separation
vacuum manifold system set at 5 mm Hg. Analyte beads
in assay buffer were added into wells, followed by 50 μl of
serum or standard solution and incubated for 30 mins at
RT with continuous shaking (at setting #3) using a Lab-
Line™ Instrument Titer Plate Shaker (Melrose, IL). The fil-
ter-bottom plates were washed as before and the buffer
was removed using a Millipore™ multiscreen separation
vacuum manifold system. Subsequently, 50 μl of anti-
mouse IL-2, IL-4, IL-6, IL-10, GM-CSF, or IFN-γ Ab-biotin
reporter solution was added in each well and the plates
were incubated with continuous shaking for 30 mins fol-
lowed by centrifugation and washing. Next, 50 μl of
streptavidin-phycoerytherin (PE) solution was added and
the plates were incubated with continuous shaking for 10
mins at RT. 125 μl of Bio-plex assay buffer was added and
Beadlyte™ readings were measured using a Luminex™ Sys-
tem and calculated using Bio-plex™ software (Bio-Rad).
The cytokine Beadlyte™ assays were capable of detecting >
5 pg/ml for each analyte.
RNA isolation and gene expression analysis
Total RNA from the spleen, ILNs, fallopian tube, uterus,
and cervix leukocytes was isolated from mouse treated
with anti-CCL5 or control Ab using Tri-reagent™ (Molecu-
lar Research Center, Cincinnati, OH). Potential genomic
DNA contamination was removed from these samples by
treatment with RNase-free DNase (Invitrogen) for 15
mins at 37°C. RNA was then precipitated and re-sus-
pended in RNA secure (Ambion). cDNA was generated by
reverse transcribing approximately 1.5 μg of total RNA
using Taqman™ reverse transcription reagent (Applied
Biosystems).
Mouse mRNA sequences of CCL5, CCR5, IFN-γ, and 18S
rRNA were obtained from the NIH-NCBI gene bank data-
base accession numbers NM03653, D83648, K00083,
and X00686.1, respectively. These sequences were then
used to design primers for real-time polymerase chain
reaction (RT-PCR) analysis, which generated amplicons of
97, 100, 98, and 149 base pairs size, respectively, for CCL5
(sense-TCG TGT TTG TCA CTC GAA GG and antisense-
GCT GAT GGC CTG ATT GTC TT), CCR5 (sense- CGA
AAA CAC ATG GTC AAA CG and antisense- GGG AAG
CGT ATA CAG GGT CA, IFN-γ (sense- ACT GGC AAA AGG
ATG GTG AC and antisense- GTT CTC CTG TGG ATC
GGG TA), and 18S rRNA (sense-GTA ACC CGT TGA ACC
CAA TT and antisense- CAA TCC AAT CGG TAG TAG CG).
Primers were designed using the primer 3 software pro-
gram from Whitehead Institute at the Massachusetts Insti-
tute of Technology (MIT). Thermodynamic analysis of
primers was conducted using the following computer pro-
grams: Primer Premier™ (Integrated DNA Technologies)
and MIT Primer III (Boston, MA). The resulting primer
sets were compared against the entire murine genome
using the National Center for Biotechnology Information
(NCBI) to confirm specificity and ensure that the primers
flanked mRNA splicing regions. cDNA was generated asBMC Microbiology 2008, 8:136 http://www.biomedcentral.com/1471-2180/8/136
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before and amplified with specific cDNA primers using
SYBR® Green PCR master mix reagents (Applied Biosys-
tems). The copy number (> 10) of mRNA relative to 18S
rRNA copies was evaluated by RT-PCR analysis using the
BioRad Icycler and software (Hercules, CA).
Statistics
Data were expressed as the mean ± standard error of mean
(SEM), compared using a two-tailed student's t-test or an
unpaired Mann Whitney U-test, and considered statisti-
cally significant if p < 0.01. When cytokine levels were
below detection (BD) limit, they were recorded as one-
half the lower detection limit (e.g., 5 pg/ml for IL-10) for
statistical analysis.
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